Articles From: The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons to Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy


The Medicines Company (NASDAQ: MDCO) today announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA™ (fibrin sealant), formerly known as Fibrocaps, at the 100 th Clinical Congress of the American College of Surgeons in San Francisco, CA.
Sign-up for The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons investment picks
— 10.6% Sales Growth — MINNEAPOLIS, Oct.
Sign-up for The Tile Shop Reports Third Quarter 2014 Results; Announces CEO Transition investment picks
MISSION VIEJO, Calif., Oct.
Sign-up for CareTrust REIT Announces NASDAQ Due Bill Trading Requirements for Special Dividend investment picks
Special Appearance by Blair Wiggins PITTSBURGH , Oct.
Sign-up for DICK'S Sporting Goods Announces Grand Opening Celebration in Naples, FL investment picks
2014/10/27
Limited-time dessert offering begins today at trend-setting restaurants nationwide DALLAS , Oct.
Sign-up for It's Baaaack! The Great Pumpkin Spice Cake Returns to Pie Five Pizza investment picks
North Carolina Utilities Commission approves Company's affiliate agreements with proposed Atlantic Coast Pipeline CHARLOTTE, N.C. , Oct.
Sign-up for Piedmont Natural Gas Receives Regulatory Approval for Atlantic Coast Pipeline Agreements investment picks
2014/10/27
By David Weidner, MarketWatch SAN FRANCISCO (MarketWatch) -- With every story on the growing pains of Apple Pay, you can read or hear comments criticizing electronic-payment systems.
Sign-up for The Apple Pay debacle is ultimately good for you investment picks
Plum Creek Timber Company, Inc. (NYSE: PCL) announced today it has reached an agreement to sell approximately 165,000 acres of Montana and Washington forestland to The Nature Conservancy (TNC) for $134 million.
Sign-up for The Nature Conservancy to Acquire 165,000 Acres of Plum Creek Forestland in Montana and Washington investment picks
Academic Health System Selects Omnicell as a Collaborative Partner to Support Pharmacy, Nurse Workflow and Increase Patient Safety MOUNTAIN VIEW, Calif.
Sign-up for Wake Forest Baptist Medical Center Will Convert to Omnicell Medication Automation Solutions investment picks
SALT LAKE CITY and ZURICH, Oct.
Sign-up for Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe investment picks
Arctic Cat Inc. (NASDAQ:ACAT) today reported net earnings of $15.4 million, or $1.18 per diluted share, on higher net sales of $262.5 million for the fiscal 2015 second quarter ended September 30, 2014.
Sign-up for Arctic Cat Reports Fiscal 2015 Second Quarter Results investment picks
2014/10/23
On Sunday, Booz Allen will debut a powerful new device that will help law enforcement and the military conduct immediate fingerprint analysis at an incident scene – saving precious time in the initial stages of an investigation.
Sign-up for Booz Allen Debuts VAMPIRE -- New Tactical Forensic Device for Law Enforcement -- at IACP Conference investment picks
Clayton Williams Energy, Inc. (NYSE: CWEI) today filed a Form 8-K with the Securities and Exchange Commission to provide financial guidance disclosures for the year ending December 31, 2014.
Sign-up for Clayton Williams Energy Provides Financial Guidance for 2014 investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today reported that the U.S. Food and Drug Administration (FDA) has extended the company’s Prescription Drug User Fee Act (PDUFA) action date for its Natpara Biologics License Application (BLA) by three months from October 24, 2014 to January 24, 2015.
Sign-up for PDUFA Action Date for Natpara® BLA Extended Three Months to January 24, 2015 investment picks
2014/10/23
The Board of Directors of The Charles Schwab Corporation has declared a regular quarterly cash dividend of $0.06 per common share.
Sign-up for Schwab Declares Regular Quarterly Common Stock Dividend and Preferred Stock Dividend investment picks
Teledyne Technologies Incorporated (NYSE:TDY) announced today that a subsidiary has acquired the business and substantially all of the assets of The Oceanscience Group Ltd.
Sign-up for Teledyne Acquires Oceanscience investment picks
2014/10/23
The first and only headset that provides wireless chat and game audio on the Xbox One SAN DIEGO , Oct.
Sign-up for Turtle Beach Stealth 500X Fully Wireless Gaming Headset for the Xbox One Now Shipping to Stores investment picks
HUTCHINSON, Minn., Oct.
Sign-up for Hutchinson Technology Announces Convertible Debt Offering and Private Exchange investment picks
2014/10/20
All-New Offering Allows Customers to 'Earn More.
Sign-up for Photo Release -- First Citizens Bank Introduces New Credit Card Rewards Program investment picks
PHILADELPHIA, Oct.
Sign-up for Beneficial Mutual Bancorp, Inc. Announces Third Quarter Results investment picks
ROSEMONT, Ill., Oct.
Sign-up for Wintrust Financial Corporation Announces Plans to Acquire Delavan Bancshares, Inc. investment picks
Phase 1 Clinical Trial Highlights: SANTA MONICA, Calif., Oct.
Sign-up for Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells investment picks
2014/10/13
NEW YORK and SAN FRANCISCO, Oct.
Sign-up for Nasdaq Educational Foundation to Open Entrepreneurial Center in San Francisco investment picks
2014/10/10
Leiden, The Netherlands, Oct.
Sign-up for Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons to Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent